Trial: 201605064

A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATING DRUG, IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR RELAPSED OR REFRACTORY HIGHER-RISK MYELODYSPLASTIC SYNDROMES

Phase

I

Principal Investigator

Uy, Geoffrey

Disease Site

Leukemia, other; Myeloid and Monocytic Leukemia; Other Hematopoietic

Learn more about this study at: clinicaltrials.gov